Varicella immunity in Iran: an age-stratified systematic review and meta-analysis
Abstract
Objectives: To generate synthesized information on the epidemiology of VZV infection, as well as an estimation of prevalence of age-specific antibody in Iranian less than 40.
Material and Methods: After exclusion of irrelevant and overlapping reports, 15 papers were included (from nine major cities). Studies were pooled according to the heterogeneity test results. Random effect model methods were used for meta- analysis where significant heterogeneity was observed (age 1-16years ).For other age groups, fixed model were used.
Results: Significant heterogeneity was observed in prevalence rates of all childhood age-groups. The seropositivity prevalence increased steeply from the age of 1-5 to 6-10 [from 21.9% (95% CI; 10.8-33.1) to 42.1 %(95% CI; 33.6-50.6)]. At the age of 11–15, 59.4% (95% CI; 46.1-72.8) of children showed to be infected. The rate of seropositivity was more than 87% in individuals of 40 and older.
Conclusion: The varicella seroeprevalence in Iran is in accordance with average tropical and temperate areas. Comparison of conducted studies during 2003 to 2011 didn’t show any alteration in VZV seroprovalence in Iran.
Whitley RJ. Varicella-Zoster Virus. In: Mandell, Douglas, and Bennett’s principles and practice of infectious diseases 7th ed. Philadelphia, PA: Elsevier Churchill Livingstone 2010: 1963–1969.
Miller E, Marshall R, Vurdien J. Epidemiology, outcome and control of varicella-zoster infection. Rev Med Microbiol 1993;4:222–230.
Gil A, Oyaguez I, Carrasco P, Gonzalez A. Epidemiology of primary varicella hospitalisations in Spain. Vaccine 2002; 20:295–298.
Sauerbrei A, Wutzler P. Herpes simplex and varicella zoster virus infections during pregnancy: current concepts of prevention, diagnosis and therapy. Part 2: varicella-zoster virus infections. Med Microbiol Immunol 2007;196: 95–102.
Harger JH, Ernest JM, Thurnau GR, Moawad A, Momirova V, Landon MB, et al. Risk factors and outcome of varicella-zoster virus pneumonia in pregnant women. J Infect Disease 2002;185:422–427.
Nguyen HQ, Jumaan AO, Seward JF. Decline in mortality due to varicella and implementation of varicella vaccination in the United States. N Engl J Med 2005;352:450–458.
Geography of Iran: facts and figures. Iran Chamber Society [http://www.iranchamber.com] webcite 2001.
The Results of Census 2006 (1385 AD) from Statistical Centre of Iran. Statistical Centre of Iran [http://www. sci.org.ir] webcite 2009.
Mor a d i-L a keh M, Est eg ha m at i A. Nat ion al Immunization Program in Iran: Whys and why nots. Hum Vaccin Immunother2013;9: 112.
Neyeloff JL, Fuchs SC, Moreira LB. Meta-analyses and Forest plots using a microsoft excel spreadsheet: step- by-step guide focusing on descriptive data analysis. BMC Res Notes2012;5: 52.
Higgins JP, Thompson SG, Deeks JJ, Altman DG.Measuring inconsistency in meta-analyses. Br Med J2003; 327(7414): 557.
U.S. Department of health and human services.National toxicology program. The Forest Plot Viewer software. Available from: http://ntp.niehs.nih.gov/go/ tools_forestplotviewer [cited March 28, 2014]
Sharifi Z, Emadi Ghanjin S. The seroepidemiology of varicella zoster (VZV) in different age groups in Tehran, Iran. Iran J Allergy Asthma Immunol 2005;4:95-98.
Ehsani pour F, Shayanfar N, Salariyan K. Surveying of protective antibody against varicella zoster virus (VZV) infection in children referring to Hazrat-e- RasoolAkram Hospital (2005). Iran Uni Med Sci J2009; 16(64) :38-44.
Pourakbari B, Shahbaznezhad L, Parvaneh N, Nikkhah S, Mahmoudi S, Teymuri M, et al. Seroepidemiology of Varicella zoster virus among children, adolescents and medical students in a referral children medical center, Tehran, Iran. Iran J Microbiol 2012;4:136–138.
Talebi-Taher M, Kashanian M, Khalili K.Seroprevalence of varicella-zoster virus among pregnant women in two teaching hospitals, Tehran, Iran. Iran J Microbiol 2014;6: 37-40.
Talebi-Taher M, Rezaie O. Seroepidemiology of VZV in the young adults referring to Rasoul-Akram Hospital in Tehran. Sci J Kurdistan Univ Med Sci 2012;17:36–42.
Motamedifar M, Handjani F, Hadi N, Shahkarami MK, Mehrabani D. Seroprevalence of varicella – zoster virus in children from Shiraz-Iran. Iran J Immunol 2006;3:43–46.
Ziyaeyan M, Alborzi A, Jamalidoust M, Moieni M, Pourabbas B. Seroepidemiology of Varicella zoster virus infection among 1–70 year individuals in Iran. Iran Red Crescent Med J 2012;12:176–180.
Pourahmad M, Davami MH, SotoodehJahromi AR.Evaluation of anti-varicella antibody in young women before their marriage: a sero-epidemiologic study in Iran. J Clin Virol 2010;48:260-263.
HosseininasabA, Arabzadeh AM, Haghdoost AA, Helmi Z. Immunity against varicella zoster virus based on history of previous chickenpox: a study in premarital Iranian women. Int J Infect Dis2013;17:e568–e569.
Barazesh A, Zandi K, Hadavand F, Moatamed N, Hefzollah F, Hefzollah B, Vahdat K. Seroepidemiology of rubella, cytomegalovirus, herpes simplex & Varicella zoster virus in college women of Bushehr. Iran South Med J 2014;16: 459-466.
Mamani M, Zamani M, Hashemi SH, Akhtari M, Niayesh A. Seroepidemiology of varicella zoster virus among pregnant women in Hamedan, Iran. Afr J Microbiol Res2012;6:1829 –1832.
Bayani M, Siadati S, Esmaeilzadeh S, Asgari S, Salmani S. Seroprevalence of Varicella zoster antibodies among pregnant women in Babol, Northern Iran. Iran J Pathol 2013;8:171–177.
TaghaviArdakani A, Soltani B, Sehat M, NamjooS.Seroprevalence and Risk Factors of Varicella- Zoster Among Children in Kashan - Center of Iran. Jundishapur J Microbiol 2013; 6: e83-88.
Farshchi A, Niayesh A. Seroprevalence of Varicella antibodies in healthcare workers in Imam Reza Hospital of Kermanshah-Iran. J Pharma& Health Sci 2012;1:37–40.
Allami A, Mohammadi N, Najar A. Seroepidemiology of varicella and value of self-reported history of varicella infection in Iranian medical students. Int J Occup Med Environ Health 2014;27:304– 313.
Talebi-Taher M, Noori M, Shamshiri AR, Barati M.Varicella Zoster antibodies among health care workers in a university hospital, Tehran, Iran. Int J Occup Med Environ Health 2010; 23: 27-32.
Talebi-Taher M, Hassanzadeh T, Ossareh Sh.Seroprevalence of antibodies against Varicella-Zoster virus among prevalent hemodialysis patients. Iran J Kidney Dis 2013;7:475-478.
Bayani M, Hasanjani-Roushan MR, Siadati S, Javanian M, Sadeghi-Haddad-Zavareh M, Shokri M, et al. Seroepidemiology of varicella zoster virus in healthcare workers in Babol, Northern Iran. Caspian J Intern Med 2013;4: 686.
Arvin AM. Immune responses to varicella-zoster virus. Infect Dis Clin North Am 1996;10:529–570.
Mohsen AH, McKendrick M. Varicella pneumonia in adults. Eur Respir J 2003; 21: 886-891.
Akram DS, Qureshi H, Mahmud A, Khan AA, Kundi Z, Shafi S, et al. Seroepidemiology of varicella-zoster in Pakistan. Southeast Asian J Trop Med Public Health 2000;31:646-649.
Liyanage NP, Fernando F, Malavige GN, Mallikahewa R, Sivayogan S, Jiffry MT et al. Sero-prevalence of varicella zoster virus infections in Colombo district, Sri Lanka. Indian J Med Sci 2007; 61:128-134.
Venkitaraman AR, Seigneurin JM, Baccard M, Lenoir GM, John TJ. Measurement of antibodies to varicella- zoster virus in a tropical population by enzyme-linked immunosorbentassay. J Clin Microbiol 1984; 20:582-583.
Ooi PL, Goh KT, Doraisingham S, Ling AE. Prevalence of varicella-zoster virus infection in Singapore. Southeast Asian J Trop Med Public Health 1992;23:22-25.
Lolekha S, Tanthiphabha W, Sornchai P, Kosuwan P, Sutra S, Warachit B, et al. Effect of climatic factors and population density on varicella zoster virus epidemiology within a tropical country. Am J Trop Med Hyg 2001;64: 131–136.
Schmid S, Jumaan AO. Impact of varicella vaccine on varicella-zoster virus dynamics. Clin Microbiol Rev 2010; 23: 202–217.
Masuet-Aumatell C, Ramon-Torrell JM, Casanova- Rituerto A, Banqué-Navarro M, Dávalos-Gamboa R, Montaño-Rodríguez SL. Seroprevalence of varicellazoster virus infection in children from Cochabamba: tropical or temperate pattern? Trop Med Int Health2013;18: 296-302.
Wutzler P, Farber I, Wagenpfeil S, Bisanz H, Tischer A. Seroprevalence of varicella-zoster virus in the German population. Vaccine 2001;20:121-124.
de Melker H, Berbers G, Hahne S, Rumke H, van den Hof S, de Wit A, et al. The epidemiology of varicella and herpes zoster in The Netherlands: implications for varicella zoster virus vaccination. Vaccine 2006;24:3946-3952.
Aebi C, Fischer K, Gorgievski M, Matter L, Muhlemann K. Age-specific seroprevalence to varicella-zoster virus: study in Swiss children and analysis of European data. Vaccine 2001;19:3097-3103.
Garnett GP, Cox MJ, Bundy DA, Didier JM, St Catharine J.The age of infection with varicella-zoster virus in St Lucia, West Indies. Epidemiol Infect 1993;110: 361–372.
Arvin AM.Varicella-zoster virus. Clin Microbiol Rev 1996; 9: 361–381.
Higgins JPT, Green S, editors. Formulating the problem. Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 [updated September 2006]; Section 8.7.3. http://www.cochrane.org/resources/ handbook/hbook.htm (accessed 6th April 2014).
Kanra G, Tezcan S, Badur S. Varicella seroprevalence in a random sample of the Turkish population. Vaccine 2002; 20:1425-1428.
Ozkan S, Maral I, Ilhan F, Aycan S, Cirak MY, Beyazova U, et al. Varicella zoster seroprevalence in children less than 5 years old. J Trop Pediatr2005;51:141-144.
Koturoglu G, KurugolZ, Turkoglu E. Seroepidemiology of varicella-zoster virus and reliability of varicella history in Turkish children, adolescents and adults. Paediatr Perinat Epidemiol 2011;25: 388–393.
Kose S, Mandiracioglu A, Senger SS, Ulu Y, Cavdar G, Gol B, et al.Seroprevalence of varicella-zoster virus in the prevaccine era: A population-based study in Izmir, Turkey. J Infect Public Health 2013; 6: 115-119.
| Files | ||
| Issue | Vol 6 No 6 (2014) | |
| Section | Articles | |
| Keywords | ||
| Iran Varicella meta-analysis seroepidemiologic study | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
